Home Blog Page 6

Grid Aero Secures Letter of Intent from Everts Air to Solve Logistic Challenges Across Alaska

0

Grid Aero, an aerospace startup focused on building the world’s most resilient autonomous air cargo network, today announced it has received a letter of intent from Everts Air, one of Alaska’s larger operators for essential air services, to deploy its Lifter Lite aircraft for freight and fuel deliveries across Alaska’s most remote communities.

“For a carrier like Everts, serving Alaska’s remote communities, the Lifter’s ability to deliver critical payloads with a fleet of smaller aircraft will be a real advantage,” said Paul Quirion, Director of Operations at Everts Air Cargo. “In our environment, where harsh weather and challenging conditions are the norm, the capability to operate safely without putting crews at risk expands both our mission reach and our reliability.”

Alaska spans more than 663,000 square miles where over 80% of communities have no road access and face extreme winter conditions, creating one of the most demanding logistics environments in the United States. Given these operational realities, Everts Air’s interest in Grid Aero centers on how the autonomous technology might eventually complement portions of their existing fleet. The Lifter Lite is designed as a long-range cargo drone capable of transporting substantial payloads across extended distances at a low cost—characteristics that directly address the challenges of serving Alaska’s remote communities.

“Grid Aero’s aircraft are purpose-built for missions like these. They’re versatile, rugged, and capable of carrying thousands of pounds over thousands of miles,” said Arthur Dubois, CEO of Grid Aero. “Whether Everts needs to deliver fuel to remote villages or urgent, on-demand cargo such as medical supplies across vast distances, our aircraft will expand their operational reach and capacity. We’re excited to demonstrate how this capability can address real-world logistical challenges across Alaska.”

To learn more about Grid Aero and its Lifter Lite, visit: www.grid.aero.

About Grid Aero

Founded in 2024 and based in San Leandro, CA, Grid Aero is pioneering the future of autonomous cargo logistics with rugged, long-range aircraft built for scale and resilience. The company’s mission is to enable a smarter, more distributed global logistics network across defense and commercial sectors alike. Learn more at: www.grid.aero.

Flow Launches Breakthrough AI Portal Automation Agent to Eliminate the Industry’s Biggest Bottleneck

0

Flow Specialty, the insurance industry’s first AI-powered placement service provider, today announced the launch of its newest innovation: AI portal automation. The technology leverages AI agents to navigate carrier portals end-to-end, a task long viewed as one of the most tedious and costly parts of insurance operations.

Carrier portals were originally intended to streamline the quoting process. Instead, they’ve slowed it down by forcing brokers to log in to several different carrier systems for each insured, manually rekey data, upload documents, and navigate inconsistent workflows for individual quotes.

Flow’s new technology automates that process almost completely, eliminating more than 95% of manual tasks. The AI agents can open a browser, log into multiple carrier portals in parallel, interpret on-screen forms, answer coverage-specific questions, upload files, and return a completed submission back to the broker, with minimal human intervention, all in a fraction of the time it takes a human.

A New Horizon for Insurance Operations

“Portals were designed to make carriers faster, not brokers,” said Sivan Iram, CEO of Flow Specialty. “In reality, they shift manual tasks downstream, forcing agencies to absorb the workload. Flow’s AI flips that dynamic, giving agencies control back over cost, quality, and distribution, automating this necessary but low-value work.”

Flow’s platform, which uses a human-in-the-loop model for quality assurance, meets the carriers where they are by integrating email, API, and portal workflows. Regardless of the submission requirements for a quote, Flow automates the process seamlessly and consistently. The result is a complete and accurate submission package that can be quickly reviewed and submitted by a Flow broker.

“The real problem with portals is that every carrier deployed its own version,” said Amit Ben Nathan, Chief Product Officer at Flow. “Each has different questions, formats, and logic trees. Our AI doesn’t just fill in forms – it understands what it’s seeing. It can interpret a portal visually and semantically, but faster and more accurately. That’s what makes this such a breakthrough.”

“This is a significant technical leap for the industry,” said Flow’s Chief Technology Officer, Naor Rosenberg. “Flow’s AI agent can operate inside complex, changing environments. It adapts to conditional questions and populates data directly from both structured and unstructured client files. It’s human-grade reasoning at machine speed, running securely in the cloud, across multiple carriers at once.”

This launch extends Flow’s mission to make small commercial accounts more profitable by drastically reducing the time spent on tedious tasks. Flow’s AI agents already power delegated placement and renewal workflows for agencies managing books of thousands of small commercial policies. With AI Portal Automation, Flow is further reducing the need for human touchpoints in repetitive, low-margin processes, helping agencies focus resources on strategic, high-value growth.

Learn more at www.flowspecialty.com.

Hemmings Brings Prestigious Chevrolet Corvette C8.R-005, Legendary Chip Foose and Hot Rod Boats to SEMA Show 2025

0

Hemmings, the world’s largest online collector car marketplace, is bringing American racing history to the 2025 SEMA Show in Las Vegas (Central Hall, Booth # 22477) with the 2020 Chevrolet Corvette C8.R-005, a factory-built endurance race car that will be simultaneously for sale on the  Hemmings.com marketplace during the show. With a body hand-crafted by Pratt Miller and powertrain built by General Motors for the Corvette Racing’s 2020–2023 International Motor Sports Association (IMSA) and FIA World Endurance Championship (FIA WEC) seasons, the C8.R introduced the mid-engine Corvette to global competition. 

Corvette Chassis C8.R-005 is one of only six made and includes a 500 hp 5.5L flat-plane V8, Xtrac 6-speed gearbox, aluminum monocoque chassis, and Bosch racing electronics. Over four years, the C8.R program scored 22 wins, 50 podiums, 23 poles, and 14 fastest laps, including major victories at the Rolex 24 at Daytona and the 24 Hours of Le Mans. 

The C8.R-005 will be available exclusively on Hemmings.com during and following its public display at the SEMA Show 2025. The listing represents a once-in-a-lifetime opportunity to acquire a factory-built championship Corvette with full documentation and ongoing support available from Pratt Miller.

“The C8.R-005 embodies the kind of rarity and excellence that define Hemmings’ commitment to collectors,” said Jonathan Shaw, President of Hemmings. “We’re honored that Pratt Miller — a name synonymous with Corvette Racing and engineering excellence — as well as General Motors have entrusted Hemmings to present this car to market. By showcasing vehicles of this caliber, we’re advancing the buying and selling experience with a level of integrity and curation that honors the heritage of car culture while inspiring its future.”

“There are only six C8.R Corvettes from the 2020-2023 Racing Program in existence and the C8.R-005 being sold on Hemmings.com was driven by Antonio Garcia, Jordan Taylor, Tommy Milner, Nicky Catsburg and Nick Tandy,” said Marc Maurini, Director of Racing Operations and former Corvette Racing Program Director for Pratt Miller. “With a vehicle this rare, it means the next owner will be adding a hand-built piece of art with a prestigious racing history to their collection.” 

See the Corvette and make an offer here: https://www.hemmings.com/auction/2020-chevrolet-corvette-mi-110245

Hemmings @ SEMA 2025: What to see, who to meet, and where to be

Beyond the show-stopping Corvette C8.R-005 display, Hemmings is bringing a full slate of experiences to SEMA Show 2025, blending collector culture, custom builds, and community energy across the entire week. Here’s where to find the action:

  • Meet the legendary Chip Foose, star of the long-running Overhaulin’ television show and one of the most respected names in car culture, during a special, Hemmings Motor Club autograph session on Wednesday, November 5 from 12 p.m. to 2 p.m. at the Hemmings booth.
  • Hemmings is hosting its annual SEMA party that will feature custom boats from the 1970s in a laid-back, after-hours environment. This will include the first public appearance of Mike Finnegan’s new hot rod boat. Stop by the Hemmings Booth for additional details while at the SEMA Show. 
  • Throughout the week, z Hemmings’ Honors Awards will be presented to up to ten standout vehicle builds on the SEMA show floor to honor excellence in design, craftsmanship, and forward-thinking builds.
  • Hemmings is proud to offer Hemmings Motor Club members a special members-only price on SEMA Show Public tickets – $113 per ticket (a $7 savings), for Friday, Nov. 7, 2025 (must be 16+ years or older to attend). This General Admission offer provides HMC members access to the largest automotive aftermarket trade show and over a thousand one-of-a-kind vehicle builds on display. 
  • Learn about Hemmings Motor Club and claim an exclusive 25 percent membership discount available only to SEMA attendees. Members take advantage of unlimited marketplace listings, 24/7 emergency roadside assistance, early listing access, and more than $1,000 in annual benefits that fuel the collector lifestyle.

To explore the 2020 Chevrolet Corvette C8.R-005 auction, browse collector vehicles, or see how Hemmings is shaping the future of the hobby, visit and subscribe at www.hemmings.com.

Hemmings and San Francisco Artist Jeremy Fish Debut Limited-Edition Collaboration Celebrating California Car Culture

0

SAN FRANCISCO, CA (October 27, 2025) — Hemmings, the world’s largest online collector car marketplace, is entering new creative territory with its first artist collaboration. The company has partnered with San Francisco illustrator Jeremy Fish to design a limited-edition t-shirt and poster that honor California’s deep connection to car culture.

“This illustration was inspired by my love and long-standing fascination with the volume of amazing classic cars that have survived in California,” said Fish.

The design, debuted at the Hemmings Motor Club Rally in Paso Robles, blends California state flag motifs with a classic late-1970s Ford Bronco, reimagined in Fish’s iconic style. The limited-edition design reflects Hemmings’ commitment to bridging its more than 70-year legacy with contemporary culture and expanding its reach to new generations of enthusiasts.

“This collaboration marks an important moment for Hemmings,” said Dan Stoner, creative director at Hemmings. “Jeremy’s work captures the spirit of California in a way that speaks to both lifelong collectors and younger fans who are discovering classic cars for the first time. It shows how art and automotive culture can come together to celebrate tradition while creating something fresh.”

Fish’s appreciation for Hemmings runs deeper than the collaboration itself. In 2020, he discovered and purchased an exceptionally preserved 1987 Toyota Corolla on the Hemmings marketplace — a Toronto import with fewer than 19,000 miles. “In my ongoing search, I found what may be one of the most immaculate daily driver Corollas in the world,” said Fish. “It’s nice to have a 40-year-old car that’s this reliable. I really appreciate Hemmings for making that kind of find possible.”

Fish is a San Francisco–based illustrator and fine artist who has spent nearly three decades shaping the city’s visual culture. His work spans galleries and museums worldwide as well as collaborations in skateboarding, streetwear, music, and public art. Known for storytelling through a cast of whimsical yet eerie characters, Fish has earned notable honors, including San Francisco City Hall’s first artist-in-residence in 2015 and Major League Baseball’s inaugural artist-in-residence with the San Francisco Giants in 2024.

Hemmings’ partnership with Fish represents a broader effort to connect the brand with the art, culture, and lifestyle communities that fuel today’s car culture.

The limited-edition t-shirt ($20 MSRP), and poster ($10 MSRP), is now available exclusively at www.hemmings.com/store. To learn more about Jeremy Fish, visit sillypinkbunnies.com

About Hemmings

Founded in 1954, Hemmings is the world’s largest online collector car marketplace. For more than 70 years, we have grown and uplifted the collector car community because we’ve been part of it since the start. Through our frictionless marketplace, quality entertainment, and professional service, we help all willing drivers buy, sell, and live the collector car lifestyle. Hemmings Motor Club extends this mission by bringing enthusiasts together through exclusive benefits, curated driving experiences, and deeper community connections for those who live to drive. More information, services, and content are available at www.hemmings.com. Stay connected with Hemmings on Facebook, Instagram, and YouTube, and search tens of thousands of vehicle listings from the palm of your hand with the Hemmings App.  

###

TSRL Awarded $2.2 Million Phase II SBIR Grant from the National Institutes of Health (NIH) to Advance Microneedle Patch for Overactive Bladder Therapy

ANN ARBOR, Mich. (October 22, 2025) – TSRL, Inc.,  a preclinical contract research organization (CRO) specializing in formulation development, bioanalysis, exploratory toxicology, and pharmacokinetic strategies to guide human dosing schedules, announced today that it has received a new $2.2 million grant award from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH) under Award Number R44DK143799, to advance the development of a weekly microneedle patch for the treatment of overactive bladder (OAB). The project focuses on delivering Trospium Chloride, a well-established but inconvenient therapy with low compliance, through a novel hydrogel-based microneedle system that improves patient tolerance and outcomes.

Overactive bladder affects millions of people in the United States and is especially common among adults over 65. While anticholinergic drugs remain a standard treatment, their effectiveness is often offset by high discontinuation rates, poor bioavailability, and serious side effects such as cognitive impairment. TSRL’s microneedle patch-based approach aims to solve these challenges by delivering Trospium Chloride—a compound that does not cross the blood-brain barrier and is considered favorable in reducing cognitive side effects—at a steady, therapeutic rate using a self-administered patch designed for weekly use.

The NIH grant supports preclinical development efforts that will generate pharmacokinetic, efficacy, and safety data in preparation for IND submission. This research is being conducted in partnership with leading advisors in transdermal delivery and urological therapeutics.

“We are proud to receive this NIH grant and to help address a serious unmet need for patients who suffer from overactive bladder,” said Dr. Elke Lipka, CEO of TSRL. “This award reflects the innovation and dedication of our team, as well as the strong potential of our microneedle platform to reshape how therapies like Trospium Chloride are delivered. Our focus is on improving quality of life through better delivery systems, and this project reflects our mission perfectly.”

TSRL has a long-standing commitment to driving pre-clinical innovation and brings decades of experience in bioanalysis, formulation development, PK/ADME and toxicology, strategic consulting, and drug delivery. The company’s 7,500-square-foot facility in Ann Arbor houses advanced formulation and bioanalytical laboratories, along with a team of scientists dedicated to moving promising therapies forward.

For more information, visit: https://www.tsrlinc.com/.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.

About TSRL, Inc.

TSRL, Inc. is a preclinical contract research organization (CRO) specializing in formulation development, bioanalysis, exploratory toxicology, and pharmacokinetic strategies to guide human dosing schedules. Based in Michigan, TSRL supports pharmaceutical, biotechnology, academic, and government partners with a science-first approach that goes beyond standard testing. As a preclinical CRO, TSRL delivers a focused set of services that help research teams move drug candidates forward. Each solution is designed to reduce development risk, generate high-quality data, and support better decision-making earlier in the process. Learn more at www.tsrlinc.com.

PumasAI Named Best Clinical Pharmacology Tech Innovator 2025 by Global Health and Pharma for the Second Year in a Row

DOVER, Del. (October 20, 2025) – PumasAI, a science-first organization that turns data into life-saving decisions faster, announced today that it has been named Best Clinical Pharmacology Tech Innovator by Global Health and Pharma (GHP) in its Healthcare and Pharmaceutical Awards 2025 program. This marks the second year in a row that PumasAI has received this honor by the media publication.

The award is part of the 10th Annual Healthcare and Pharmaceutical Awards, which celebrates organizations shaping the future of global health through research, innovation, and technology. According to program administrators, PumasAI stood out for its forward-thinking approach to pharmacometric modeling and simulation, clinical pharmacology analysis and reporting, and machine learning tools, as well as its commitment to improving the ability to support faster, smarter clinical decisions.

“To be recognized by GHP for the second year speaks directly to the quality of our team and the real impact of our technology,” said Dr. Vijay Ivaturi, Co-founder and CEO, PumasAI. “Together, we are focused on creating value by developing tools that help development teams work faster, think deeper, and move closer to delivering new therapies to patients.”

GHP’s judging panel evaluates nominees based on public research and submitted materials. Criteria include measurable innovation, global contribution, continued growth, customer feedback, and dedication to healthcare advancement. All selections are made on merit through an independent review process.

Ivaturi added, “Our product engineers, pharmacometricians and clinical pharmacologists are building the change that they want to see. The innovations coming out of PumasAI illustrate the kind of thinking that our industry needs. They are shaping new approaches, asking better questions, and creating tools that help teams move with more clarity and speed across the entire development process.”

Learn more about PumasAI’s pharmaceutical and biotechnology industry innovations at https://pumas.ai/our-products.

About PumasAI

PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software and AI tools developed by the company include an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle as well as a range of specialized solutions for data analytics, machine learning, clinical trial optimization, and regulatory compliance. Scientists at PumasAI partner with leading pharmaceutical innovators, providing expert consulting in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more. By streamlining modeling, simulation, and data analytics, their solutions empower scientists and pharmaceutical partners to accelerate breakthroughs and deliver transformative healthcare.

For additional information, visit www.pumas.ai

MMS Named Finalist in the Fierce Life Sciences Innovation Awards for KerusCloud® Clinical Trial Simulation Platform

0

MMS, a global, data-focused clinical research organization (CRO), announced today that it has been named a finalist in the 2025 Fierce Innovation Awards: Life Sciences Edition for its clinical trial simulation platform, KerusCloud®. Recognized as one of the top solutions in the Data Analytics and Business Intelligence category, KerusCloud® has successfully demonstrated a powerful, data-driven impact by making clinical trial design more cost-effective, efficient, and scientifically robust and accelerating development strategies across therapeutic areas.

KerusCloud® empowers biotechnology and pharmaceutical organizations to explore thousands of virtual clinical trial scenarios using real-world data and statistical accuracy before entering the clinic. By simulating design elements such as endpoints, recruitment rates, and estimands, research teams can make faster, more informed decisions to ultimately improve trial execution and boost the probability of regulatory and commercial success.

“At MMS, innovation means creating forward-thinking, practical solutions that directly address the real-world challenges of clinical development,” said Mohamad Zahreddine, Chief Technology Officer at MMS. “We’re honored that the Fierce Innovation Awards have recognized our commitment to transforming data into meaningful insights. As we continue to expand our global footprint and advance our capabilities in analytics and AI, our mission remains clear — to empower Sponsors with scalable, data-driven tools that accelerate development and deliver life-changing therapies to patients around the world.”

Continuous Innovation Expands KerusCloud’s Strategic Value

This latest honor from the Fierce Innovation Awards supports a series of significant recent product innovations that strengthen KerusCloud’s statistical depth, computational performance, and user experience, further extending its impact in high-need therapeutic areas such as oncology and for supporting complex decision-making.

Recent innovations include:

  • New statistical features such as Restricted Mean Survival Time (RMST) and event-driven interim analyses to support oncology-specific clinical trial designs.
  • Support for decision-point modeling and multiplicity handling, helping Sponsors evaluate tradeoffs across multiple trial configurations.
  • Cloud compute optimization, with customizable AWS instance selection per clinical trial simulation task to enhance performance and cost-efficiency.
  • Improved user interface and experience, delivering faster response times, enhanced visualization interactivity, and better control over clinical trial simulation output for quality checks and decision support.

Aiden Flynn, SVP of Statistical Consulting at MMS, added, “These enhancements further establish KerusCloud® as a strategic and innovative simulation platform that evolves in step with emerging data. For biotech and pharma teams aiming to de-risk development early, KerusCloud® provides the insight and confidence needed to design stronger, more efficient programs that deliver value to both Sponsors and investors.”

Earlier this year, MMS was honored by winning the 2025 Fierce CRO Award in the category of Excellence in Client Service and Partnership and CEO Dr. Uma Sharma earned the CRO Champion Award.

To learn more about KerusCloud or request a demonstration, visit: https://mmsholdings.com/ai-technology/keruscloud-clinical-trial-simulation/.

Trialt Launches New Brand Identity and Website to Signal a New Era in Biometrics and Medical Writing CRO Services and Solutions

0

NEEDHAM, Mass. (October 14, 2025) – Trialt, a global clinical research organization (CRO) specializing in biostatistics, statistical programming, data management, and medical writing, has unveiled its refreshed brand identity and newly redesigned website at www.trialt.com. The rebrand signals a new chapter for the company, bolstering its reputation as a fast-moving, deeply technical partner that pharmaceutical and biotechnology sponsors can trust across critical clinical milestones.

The visual refresh includes a modernized logo, fonts, and visuals, as well as an updated design system that supports clearer storytelling across digital platforms, proposals, and other sponsor touchpoints.

“We’ve always delivered results that speak for themselves,” said Yaroslav Sud, VP of Biometrics at Trialt. “This brand refresh gives us the visual language and presence to match that delivery. It’s clean, credible, and forward-looking, reminiscent of our solutions-oriented approach to solving sponsor challenges.”

A Clearer Path for Sponsors

The new website makes it easier for clinical trial sponsors to understand how Trialt works and how collaboration can be structured to fit the complexity of a study or scale of a program. Highlights include the following:

  • A strong overview of services and solutions, including biostatistics, statistical programming, data management, and medical writing.
  • A breakdown of collaboration models, including functional service provider (FSP), hybrid, full-service, and rescue.
  • Success metrics that show the company’s pace and precision, including recent rescue delivery of 72 TLFs and compliant datasets in three weeks.
  • A new Insights section to share team insights, news, events, and articles from across Trialt’s 8-country footprint.

Yaroslav added, “Our goal is to show excellence across every touchpoint to emerge as the CRO partner that sponsors turn to first when timelines are tight, stakes are high, and clarity matters most.”

Last month, Trialt was awarded a Gold Stevie® Award for Company of the Year in the pharmaceutical industry in the 22nd Annual International Business Awards®.

To learn more about Trialt’s services, visit www.trialt.com.

TrialAssure Introduces Enhanced Architectural Techniques to Improve Accuracy, Visibility, Traceability, and Control Across its AI Platform for Pharma and Biotech

Innovative application architecture gives users clearer insight into AI responses, improves output reliability, and strengthens data alignment across LINK AI®, ANONYMIZE®, and REGISTRY®

TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced the launch of its new enhanced content search and sourcing capability, a technical upgrade designed to boost accuracy, transparency, and reliability across its suite of AI-powered tools. This advancement enables a more structured way for artificial intelligence (AI) to interpret, segment, and retrieve information from source documents, enabling users to gain more precise insights and greater control over the content.

TrialAssure has introduced an integrated framework that leverages AI Large Language Models (LLMs) to process and manage content more effectively. This framework emphasizes efficient document ingestion and chunking, optimized embedding and indexing, structured information storage, and advanced AI prompt design and engineering.

These techniques replace the out-of-the-box indexing and retrieval approaches and improve the visibility and traceability of AI responses, giving users greater confidence and a more efficient approach to generating structured and regulated documents in the life sciences arena.

This also creates a more flexible and tailored experience, allowing AI models to separate, label, and group source material with greater specificity. For instance, information used to create clinical narratives can now be isolated by individual trial participants to eliminate cross-contamination and improve document fidelity.

“Giving the pharma and biotech industry clarity into how AI reaches its outputs was a technical challenge at first, but it is our usability promise,” said Zach Weingarden, MS, Director of AI Technology & Applications, TrialAssure. “We are focused on raising the standard for how AI can operate transparently in highly regulated environments like life sciences.”

Less Prompting and Increased Visibility into AI Reasoning

With the integrated approach to source management, TrialAssure product users can expect more accurate results with less time spent on prompt refinement. Instead of engineering detailed prompts to achieve clarity, users have the option now to simply point to the exact source or file that they wish the model to reference and pull from a pre-built library of prompts. This feature improves output quality across use cases, especially when working with sensitive regulatory documents.

TrialAssure’s new architecture also helps resolve the common concern that AI outputs feel like a “black box,” said in numerous industry conversations. Now, users can view the specific sentences and document sections the AI used to generate each response. An upcoming visual user experience update will illustrate the exact areas within a source document that contributed to the generated text to provide a clear audit trail and increase trust from internal and external teams from AI outputs.

Shared Benefits Across all TrialAssure Tools

The enhanced indexing feature was built into LINK AI® to support document drafting, and it is already being applied across TrialAssure ANONYMIZE® and TrialAssure REGISTRY®. For reference, this feature helps in the following ways:

  • LINK AI®: Improves traceability and relevance of AI-generated paragraphs, helping streamline submission-quality clinical document creation.
  • ANONYMIZE®: Enhances source targeting during redaction and anonymization tasks, improving alignment between context and masking decisions.
  • REGISTRY®: Supports better mapping of fields and reference data, helping users validate where the model is pulling from and refine clinical trial results disclosure more precisely.

“This advancement shows the true depth of talent across TrialAssure’s product and technical teams,” said Prasad M. Koppolu, COO, TrialAssure. “We take great pride in building solutions that anticipate real-world needs in clinical research and the transparency field at large. By blending AI advancement with the right level of human knowledge, our team continues to push boundaries globally.”

To learn more about TrialAssure’s AI capabilities or request a demonstration of enhanced indexing, visit www.trialassure.com.

PumasAI Unveils PumasAide, a Built-In AI Assistant to Accelerate Pharmacometric Research

PumasAI, a science-first organization that turns data into life-saving decisions faster, has officially launched PumasAide, an intelligent assistant that integrates directly into the pharmacometric workflow. By combining trusted scientific models with built-in artificial intelligence, PumasAide helps researchers analyze data, generate code, and complete routine clinical pharmacology and pharmacometrics tasks with unmatched speed.

PumasAide works inside environments like Visual Studio Code and other IDEs, allowing scientists to run analyses and build models in real time. It works on live data, supports AI from multiple providers, and keeps sensitive information secure by staying fully local.

Key features of PumasAide include:

  • Embedded AI Assistant: Built into the coding environment to reduce switching and friction
  • Real-Time Execution: Instantly runs live analyses like NCA and PK modeling, among others
  • Smart Code Generation: Writes, explains, and debugs Julia/Pumas code with accuracy
  • Multi-Agent Support: Delegates different steps to specialized agents working together
  • Audit-Ready: Keeps a full prompt and code trail while maintaining local data security

“PumasAide brings scientists closer to their data and decisions,” said Dr. Vijay Ivaturi, CEO and Co-Founder, PumasAI. “We designed it to help new users get started quickly and to give experienced pharmacometricians a trusted assistant to scale their impact.”

A Proven Track Record of Scientific Innovation

Since its founding, PumasAI has focused on bringing advanced science and automation into clinical pharmacology. The company has released a series of tools that build toward this vision:

  • Pumas 1.0 (2020): Modeling and simulation engine
  • Pumas 2.0 (2021): Visualization and reporting updates
  • 2022: Advanced algorithms such as SAEM
  • 2023: PumasCP graphical interface for non-compartmental analysis
  • 2024: Launch of DeepPumas and AskPumas for AI-guided modeling
  • 2025: PumasAide introduces a fully embedded, AI-powered assistant

Each launch builds on the last, with PumasAide marking a new phase in accelerating insight and reducing bottlenecks across the drug development lifecycle.

Dr. Ivaturi added, “Innovation like this is how we clear the path for scientists to think bigger, move faster, and deliver breakthroughs that improve lives.”

For more information and to receive a demo of PumasAide, visit https://pumas.ai.

About PumasAI

PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software and AI tools developed by the company includes the Pumas suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more.

For additional information, visit www.pumas.ai